EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Pyxis Oncology Inc (PYXS) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Pyxis Oncology Inc $0.41, price $2.19, upside -81.3%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US7473241013

PO Pyxis Oncology Inc logo Thin data Oct 2, 2026

Pyxis Oncology Inc

PYXS · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.4100 · Strongly overvalued (−81.3%)
!Quality 29/100
!Weak Growth (revenue YoY −14.2 %/yr)
!negative free cash flow
!Trails peers (1/7)
!Narrow moat 10/100
!Insider activity 35/100
!Evidence only low, so the estimate is less certain
Watch Pyxis Oncology Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$13.64 $0.8773 Fair Value $0.4100 Oct 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range $0.8773 – $13.64 · fair‑value band $0.2700 – $0.5100 · the $2.19 price screens above the $0.4100 fair value. Dashed = 300-day average. As of Oct 2, 2026.

Follow Pyxis Oncology in your weekly email

Every Wednesday you see whether Pyxis Oncology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.

Show more

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Stock analysis

Pyxis Oncology Inc (PYXS) currently trades at $2.19, while our model-based Fair Value estimate is $0.4100, 81.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.2700 (bear) to $0.5100 (bull), the price of $2.19 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Pyxis Oncology Inc reported revenue of $13.9M in FY2025 versus $0 in FY2021. Reported net income was −$79.6M in FY2025.

Key figures

Market cap $194M · P/S ratio 17.6 · EPS (TTM) $−1.40 · Return on equity −179% · Return on assets (EBIT) −56.0% · Operating margin −813% · Revenue (TTM) $11.0M · Free cash flow −$63.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high and 107% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −81%, PYXS screens richer than that median.

Fair Value models

Bear $0.2700 Fair Value $0.4100 Bull $0.5100
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.3200 $0.4300 $0.6400 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.3200 $0.4300 $0.6400 51

Open the full fair value analysis →

Notify me when PYXS reaches fair value

Put PYXS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 31 · Market factors (momentum, volatility) 42

Profitability 5
Margins and returns on capital today
Quality Growth 15
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 61
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 18
Calm price path (market factor)
Momentum 67
Price trend over the last 3–12 months (market factor)
52W Momentum 29
Distance to the 52-week high (market factor)
Net Issuance 25
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PYXS screens overvalued: fair value 81% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Pyxis Oncology Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 631 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −76.8% · Bottom 25%
Profitability
Return on assets −51.9% · Bottom 25%
Growth and dividend
Revenue growth 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.71× · Pricier than median
P/S (TTM) 10.45× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$176.95 A$194.65 +10%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pyxis Oncology Inc · Fair Value
$0.4100 −81%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Pyxis Oncology Inc Fair Value". https://www.fairvalue-calculator.com/stock/PYXS

Frequently asked questions

Is Pyxis Oncology Inc (PYXS) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of $0.4100 versus a price of $2.19, about −81% upside (overvalued).
What is the fair value of PYXS?
Our model-based fair value for Pyxis Oncology Inc is $0.4100 (as of Oct 2, 2026), built from audited fundamentals. The current price: $2.19.
What is the quality score of PYXS?
Pyxis Oncology Inc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pyxis Oncology Inc (PYXS)?
Our model-based price target is the fair value of $0.4100 (as of Oct 2, 2026) from 1 valuation models. Cautious scenario $0.2700, optimistic scenario $0.5100. It is a calculation from audited fundamentals, not an analyst target.
What is the Pyxis Oncology Inc stock forecast for 2026?
Our models put fair value at $0.4100, about −81% upside versus a price of $2.19 (overvalued). Cautious scenario $0.2700, optimistic scenario $0.5100. The calculation is refreshed regularly with new filings.
What is the revenue of Pyxis Oncology Inc (PYXS)?
Pyxis Oncology Inc reported trailing-twelve-month revenue of about $11.0M (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Pyxis Oncology Inc (PYXS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pyxis Oncology Inc it is $0.4100 per share (as of Oct 2, 2026), against a price of $2.19. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Pyxis Oncology Inc stock overvalued or undervalued in 2026?
As of Oct 2, 2026, PYXS trades above its calculated fair value: price $2.19, fair value $0.4100, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PYXS?
No. The price is what the market pays today ($2.19); the fair value is what the company's own numbers justify ($0.4100). For Pyxis Oncology Inc the two are $1.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pyxis Oncology Inc worth?
The market values Pyxis Oncology Inc at about $194M (market capitalisation, as of Oct 2, 2026). Per share that is $2.19; our models calculate a fair value of $0.4100 per share.
What do the bullish and bearish scenarios say about PYXS?
Our models span a range for Pyxis Oncology Inc: cautious scenario $0.2700, base $0.4100, optimistic $0.5100 per share (as of Oct 2, 2026, price $2.19). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pyxis Oncology Inc (PYXS)?
Balance-sheet figures for Pyxis Oncology Inc (as of Oct 2, 2026): return on equity −121.7%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is PYXS from its 52-week high?
Pyxis Oncology Inc trades at $2.19, about 59% below its 52-week high of $5.34 and 107% above the low of $1.06 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4100 is for.
Which stocks are comparable to Pyxis Oncology Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pyxis Oncology Inc stock attractive at the current price?
The data as of Oct 2, 2026: price $2.19, calculated fair value $0.4100 (−81%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PYXS calculated?
We run Pyxis Oncology Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Pyxis Oncology Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pyxis Oncology Inc (PYXS)?
The closing price on Oct 1, 2026 was $2.19. Our model-based fair value is $0.4100, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pyxis Oncology Inc right now?
The price sits above even our optimistic bull case ($0.5100). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2700 to $0.5100) leaves room in how you read the outcome.

Key figures of Pyxis Oncology Inc

How large is the market capitalisation of Pyxis Oncology Inc (PYXS)?
The market capitalisation of Pyxis Oncology Inc is $194M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pyxis Oncology Inc (PYXS)?
The price-to-sales ratio of Pyxis Oncology Inc is 17.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pyxis Oncology Inc (PYXS)?
Earnings per share at Pyxis Oncology Inc are $−1.40. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Pyxis Oncology Inc (PYXS)?
The return on equity (ROE) of Pyxis Oncology Inc is −179% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pyxis Oncology Inc (PYXS)?
On an EBIT basis the return on assets of Pyxis Oncology Inc is −56.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pyxis Oncology Inc (PYXS)?
The operating margin of Pyxis Oncology Inc is −813% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Pyxis Oncology Inc (PYXS) generate?
The free cash flow of Pyxis Oncology Inc is −$63.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pyxis Oncology Inc (PYXS) carry?
The net debt of Pyxis Oncology Inc is $3.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pyxis Oncology Inc in the live analysis

One click puts Pyxis Oncology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.